Introduction
World-wide, injecting drug users ( IDU) represent a high risk group for bloodborne viral infections, including HIV 1 , hepatitis B ( HBV ) 2 and hepatitis C ( HCV ) 3 . Harm reduction strategies 4 have been advocated in order to prevent spread of bloodborne viral infection and many believe that these approaches have contributed to a reduced incidence of HIV 5, 6 . There is only limited evidence that needle exchange attendance is associated with a reduction in HCV and HBV infections 7 . A recent study of the incidence of HCV infection among IDU failed to find a reduction in those who attended for methadone maintenance therapy 8 . There is a concern that current approaches may not be adequate to reduce the occurrence of unsafe injecting practices to a sufficiently low level to ensure a low incidence of HCV in populations of IDU where the prevalence of HCV is already high 3 . It is possible for harm reduction programmes to appear effective by minimising new cases of HIV while having little impact on HCV.
In Dublin harm reduction strategies have been in existence since 1989. These services have vastly expanded in the 1990's. The number of official needle exchange centres in the city has grown from one to 12 since 1990, the number of community outreach workers has trebled in the same period and access to methadone treatment has improved with the addition of four new addiction treatment centres and 12 satellite clinics. Trinity Court is the largest and longest established treatment centre in Dublin. Referrals are accepted from all areas of the city. New attenders tend to present early in their injecting careers. Patients with a history of injecting are encouraged to agree to screening tests for HIV, HBV and HCV. We sought to measure the prevalences of these viral infections against the background of the expanding harm reduction programme. We report here the results of the first five years of this data collection.
Viral markers
Prior to July 1993, the screening test for HCV was a second generation enzyme linked immunosorbant assay (EIA) for anti-HCV ( Ortho Diagnostics, Amersham, Buckinghamshire, England ). Subsequently, the third generation EIA was used. All positive results were confirmed with an additional EIA. A recombinant immunoblot assay was used in situations where the two EIA gave contradictory results. The screening test for HBV was an EIA for hepatitis B surface antigen.
The initial screen for HIV was with two EIA tests for antibody to HIV. Positive tests were confirmed with the Western blot assay.
Statistical methods
Confidence intervals were calculated by using exact methods for proportions. analyses were performed using logistic regression and variables found to be significant on univariate analyses were entered into the regression equation 9 .
Results
Of 733 attenders, 453 were anti-HCV positive ( 61.8%, 95% confidence interval 58.3 -65.3% ). Table 1 There was no significant association between any combination of the three viral markers.
Discussion
There are four possible areas of methodological concern in this study. Firstly, no data are presented on the reported frequency of unsafe injecting practices. Such practices are best examined via a standardised and detailed structured interview and possibly requiring an interviewer independent of treatment services 10,11 . Due to the long term nature of this ongoing study, there was no practical way of overcoming these obstacles and we therefore decided that no data on this area would be better than data of questionable reliability. Secondly, the daily drug expenditure was taken as a crude measure of daily drug use and injecting frequency. However, the 'street' price of heroin reduced by nearly 50% over the study period, falling to Ir£20 per 'quarter gram' in 1996-97. A third possible source of concern could be the change in the HCV screening test from a second generation to a third generation EIA early in the study period.
Although the enhanced specificity of the third generation test substantially increases the Johnson has reported a HIV prevalence of 14.8% among IDU attending a Dublin needle exchange in 1991 17 . The prevalence detected among our study group is very much lower (1.2%). This reduction is striking but it must be noted that the group studied here are younger and injecting histories are shorter than the previously studied group. Our data demonstrates a sustained low prevalence of HIV among new attenders to our treatment service. In their review of cities with sustained low prevalence of HIV among IDU, Des Jarlais and colleagues have described three features which they considered 
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Hepatitis C is associated with substantial morbidity and mortality 18 . Current harm reduction strategies appear ineffective in protecting IDU from this infection 8, 19 .
Proposed novel adaptations to these strategies will attempt to educate IDU ( or potential IDU ) during, or before, the narrow 'window of opportunity' and may in time prove beneficial 16 . In Europe, increasing numbers of drug misusers are being introduced to heroin through 'chasing the dragon' before possibly progressing on to injecting 20 .
Education of this group regarding safe injecting and the risk of HCV should be considered. Overall, we believe that in Dublin, among IDU who commenced injecting in this decade, our data supports the view that hepatitis C will create a larger health burden than either hepatitis B or HIV/AIDS. Harm reduction approaches should adapt to this change in need. Hence, while the low prevalence of HIV must be welcomed, any decision by policy makers that funds could now be diverted away from harm reduction would be very premature.
